reports
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- Jakub Krawczyk
- Jakub Krawczyk
- Andreas Riemann
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
Coloplast AS: 1 director
A director at Coloplast AS bought 4,362 shares at 458.590DKK and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Coloplast A/S - Allokering af aktieoptioner
Coloplast A/S - Allokering af aktieoptioner Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med Coloplast aktier og tilknyttede værdipapirer I henhold til Markedsmisbrugsforordningen art. 19 skal Coloplast indberette oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med Coloplast aktier og tilknyttede værdipapirer. Transaktionen omhandler allokeringer af aktieoptioner. For yderligere information henvises til Coloplasts vederlagspolitik som er tilgængelig på Coloplasts hjemmeside: 1Nærmere oplysninger om personen med ledelsesansvar/per...
Coloplast A/S - Allocation of Share Options
Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: Details of the person discharging managerial responsibilities/p...
- ABGSC Retail Research
- Alice Beer
- Benjamin Wahlstedt
- Fredrik Ivarsson
Coloplast udnævner Gavin Wood som ny CEO
Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.